Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...
Seeking Alpha

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...
Seeking Alpha

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Nasdaq

Recursion to Report First Quarter 2025 Financial Results on May 5, 2025

Recursion is scheduled to report its first quarter 2025 financial results, providing transparency and updates to investors, which can enhance trust and investor relations. The company'searnings ...
Yahoo Finance

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...